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Abstract 
Objective: Glasgow prognostic score (GPS), an inflammation-based scoring system, has been evaluated in various 
cancers. However, its clinical significance remains unclear in non-small cell lung cancer (NSCLC). Therefore, it is neces-
sary to conduct a meta-analysis to explore the prognostic value of GPS in NSCLC patients.
Methods: A quantitative meta-analysis was performed through a systematic search in PubMed, Web of Science, and 
the Cochrane Library. The pooled hazard ratios (HRs) of overall survival (OS) were calculated and compared.
Results: A total of 12 studies comprising 2669 patients were included in this meta-analysis. Compared with GPS 
0 group, patients in GPS 1–2 group exhibited a reduced OS with a pooled HR of 1.89 (95 % CI 1.57–2.27, p < 0.001; 
I2 = 54 %). Six studies had sufficient data to calculate HRs of OS for GPS 1 and GPS 2 groups. Analysis revealed that 
GPS 2 group had a statistically significant reduced OS compared with GPS 1 group with a pooled HR of 1.87 (95 % CI 
1.18–2.97, p = 0.008; I2 = 72 %). Study type (retrospective vs. prospective) and disease stage could partially explain 
the heterogeneity of each study by subgroup analysis.
Conclusion: Pretreatment GPS could serve as a simple and reliable prognosis predictor for NSCLC. More well-
designed studies that consider GPS as a stratification factor are warranted.
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Background
For many decades, lung cancer has been the most com-
mon cancer and the leading cause of cancer death world-
wide (Ferlay et  al. 2010). Non-small cell lung cancer 
(NSCLC) accounts for approximately 80  % of lung can-
cer. Surgery, chemotherapy and radiotherapy are three 
primary treatment modalities for NSCLC. The current 
staging system, namely the TNM staging system, pro-
posed by American Joint Committee on Cancer (AJCC) 
is widely used in clinical practice. However, the current 
TNM staging system is inadequate to predict progno-
sis. Prognosis differs in most cases, even for patients 
in the same stage. For example, approximately 30  % of 
early-stage patients experienced tumor recurrence and 
a poor prognosis although adequate radical treatment 
was administered. In recent decades, systematic inflam-
mation has been thought to play a crucial role in tumori-
genesis and serve as a hallmark of cancer (Hanahan and 
Weinberg 2011). The Glasgow prognostic score (GPS) 
is an inflammation-based scoring system that is evalu-
ated by two serum indicators: C-reactive protein (CRP) 
as an indicator of systematic inflammatory response and 
albumin, which reflects nutritional status (Bremnes et al. 
2011; Liao et  al. 2014; Forrest et  al. 2004; Leung et  al. 
2012; Pinato et  al. 2014). Several studies have reported 
the correlation between GPS and NSCLC patients; how-
ever, due to differences in the inclusion criteria of NSCLC 
patients and limited sample sizes undermining its role, its 
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significance in patients with NSCLC has not been fully 
studied. Considering that the GPS is currently widely 
studied for different types of cancers, including NSCLC, 
a systemic comparison to further clarify its clinical util-
ity is needed. Therefore, this study aimed to explore the 
prognostic value of GPS in NSCLC using a quantitative 




A systematic search was performed in PubMed, Web of 
Science, and the Cochrane Library from January 1, 1966 
to August 31, 2015. The search strategy used both MeSH 
terms and free-text words to increase sensitivity. The fol-
lowing search terms were used: “inflammation-based 
score”, “Glasgow prognostic score”, “GPS”, and “non-small 
cell lung cancer”.
Inclusion and exclusion criteria
The following inclusion criteria were used: (1) articles 
investigating the relation of GPS and prognosis for NSCLC 
patients; (2) serum was collected before surgery or other 
treatments; (3) patients were grouped according to the 
GPS; (4) GPS 0/1/2 was defined as none/only one/both 
elevated CRP (>10 mg/L) and hypoalbuminemia (<35 g/L). 
The following exclusion criteria were used: (1) letters, edi-
torials, expert opinions, case reports and reviews; (2) stud-
ies without usable data; (3) duplicate publications.
Data extraction
Two investigators independently extracted data from 
the eligible studies, and disagreements were resolved by 
discussion with a third investigator. For each study, the 
following information was recorded: first author, publica-
tion year, country, sample size, TNM stage, therapy, and 
overall survival (OS).
Statistical analysis
The hazard ratios (HRs) were extracted as described 
in our previous publication (Zhu et  al. 2015). The pro-
cedure is briefly outlined: (1) obtain the HRs directly 
from the publication; HRs from multivariate analysis are 
an option when HRs from univariate analysis were also 
available; (2) estimate the HRs from O-E statistic and 
variance; (3) calculate the HRs from data, including the 
number of patients and events at risk in each group, and 
the log-rank statistic or the p value; (4) retrieve HRs from 
Kaplan–Meier Curves by extracting several survival rates 
at specified times from the curves. Statistical analyses 
of HRs for OS were calculated by Review Manager Ver-
sion 5.3 (Revman, the Cochrane Collaboration, Oxford, 
England). The heterogeneity of the data was evaluated by 
Chi square Q test and I2 statistic. For the Q test, a p value 
<0.05 indicated significant heterogeneity; for the I2 statis-
tics, an I2 value greater than 50 % was considered signifi-
cant heterogeneity. Statistical significance was defined as 
a p value <0.05.
Results
Characteristics of included studies
As shown in Fig.  1, the electronic search yielded 226 
records. After screening titles and abstracts, 23 full-text 
articles were assessed for eligibility. Finally, a total of 12 
articles met the inclusion criteria and were included in 
this meta-analysis (Forrest et al. 2004; Leung et al. 2012; 
Pinato et al. 2014; Miyazaki et al. 2015; Kishi et al. 2015; 
Kawashima et  al. 2015; Jiang and Lu 2015; Grose et  al. 
2015; Tomita et al. 2014; MacKenzie et al. 2014; Rinehart 
et al. 2013; Meek et al. 2010). Among these 12 articles, six 
were retrospective, and six were prospective studies. Six 
studies were from United Kingdom, four from Japan, one 
from China, and one from America. Details are summa-
rized in Table 1.
Association between GPS and OS
In total, 12 studies of 2669 patients compared OS 
between GPS 0 and GPS 1–2 groups. The random-effects 
model was adopted as the significant heterogeneity 
(I2 = 54 %, p = 0.01). Analysis revealed a pooled HR of 
1.89 with 95  % CI 1.57–2.27 (p  <  0.001) (Fig.  2). Com-
pared with GPS 0 group, patients in GPS 1–2 group had 
a significantly poor OS, suggesting pretreatment GPS had 
the ability to predict prognosis.
Six studies had sufficient data to calculate HRs of OS 
between GPS 1 and GPS 2 groups. Because significant 
Fig. 1 The flow diagram of this meta-analysis
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heterogeneity existed among the studies (I2  =  72  %, 
p = 0.003), the random-effects model was adopted. Anal-
ysis revealed a pooled HR of 1.87 (95  % CI 1.18–2.97, 
p = 0.008) (Fig. 3). GPS 1 group had a significantly pro-
longed OS compared with GPS 2 group, indicating an 
increased risk of patients with both elevated CRP and 
hypoalbuminemia.
Subgroup analysis
As significant heterogeneity was noted across the studies, 
we further investigated potential sources of heterogeneity 
by subgroup analysis.
We first explored the impact of study type (retro-
spective vs. prospective) on heterogeneity. Six retro-
spective studies had a pooled HR (GPS 0 vs. GPS 1–2) 
of 2.38 (95  % CI 1.76, 3.20) with small heterogeneity 
(I2 = 49 %, p = 0.08), and six prospective studies had a 
pooled HR (GPS 0 vs. GPS 1–2) of 1.58 (95  % CI 1.37, 
1.83) with small heterogeneity (I2 = 3 %, p = 0.40). Next, 
we explored the influence of disease stage on heterogene-
ity. Five studies including stage IV or inoperable patients 
had a pooled HR (GPS 0 vs. GPS 1–2) of 1.61 (95 % CI 
1.34, 1.94) with small heterogeneity (I2 = 21 %, p = 0.28). 
These results indicate that pretreatment GPS might pre-
dict prognosis well.
Discussion
The current study is a quantitative meta-analysis eval-
uating the prognostic value of GPS in patients with 
NSCLC. The pooled estimates of 12 studies involving 
2669 patients indicated that patients with elevated GPS 
were predisposed to exhibit inferior survival outcome 
Table 1 Characteristics of studies in this meta-analysis
Surg surgery, SBRT stereotactic body radiation therapy, RT radiotherapy, Chemo chemotherapy
Study name Region Study type Sample size Stage Therapy
Total GPS 0 GPS 1 GPS 2
Miyazaki et al. (2015) Japan Retrospective 97 65 32 I Surg
Kishi et al. (2015) Japan Retrospective 165 100 65 I SBRT
Kawashima et al. (2015) Japan Retrospective 1043 897 107 39 I–III Surg
Jiang and Lu (2015) China Prospective 138 95 32 11 III–IV Chemo
Grose et al. (2015) UK Prospective 120 50 49 21 I–III Surg/RT/Chemo
Tomita et al. (2014) Japan Retrospective 312 264 31 17 I–III Surg
Pinato et al. (2014) UK Prospective 220 131 39 29 I–III Surg
MacKenzie et al. (2014) UK Retrospective 97 – – – I–III Surgery/RT
Rinehart et al. (2013) USA Prospective 51 9 32 10 IV Chemo
Meek et al. (2010) UK Retrospective 56 19 31 6 Inoperable II–IV RT/Chemo
Forrest et al. (2004) UK Prospective 109 27 69 13 Inoperable III–IV Chemo
Leung et al. (2012) UK Prospective 261 59 163 39 Inoperable III–IV RT/Chemo
Fig. 2 The pooled HRs of OS for GPS 0 versus GPS 1–2
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(HR 1.87: 1.18–2.97, p = 0.008). The significant relation-
ship between GPS and OS was assessed in all the sub-
group analyses stratified by the study type (retrospective 
vs. prospective) and different stages (early stage vs. stage 
IV or inoperable). The results indicate that GPS can be 
a practical indictor to predict NSCLC patient prognosis.
Inflammation plays an important role in tumor occur-
rence and development (O’Callaghan et al. 2010; Tauler 
and Mulshine 2009). GPS, which is an inflammation-
based score combining serum CRP and albumin, was 
first proposed by Forrest et  al. (2003). Subsequently, 
its clinical significance has been evaluated in various 
tumor types, including hepatocellular carcinoma, gas-
tric cancer, prostate cancer, and colorectal cancer. CRP, 
a non-specific acute reactant protein of inflammation, 
is synthesized in hepatocytes and in response to release 
of cytokines, such as interleukin 6 release by monocytes 
and other immune cells under infection, tissue necro-
sis, and inflammatory disease (Pepys and Hirschfield 
2003). As a component of the inflammatory response of 
the immune system, CRP exerts important role in the 
tumor-host interaction (Ballou and Lozanski 1992; Cer-
mak et  al. 1993), and elevated CRP is associated with 
impaired T lymphocytic response within the tumor (Du 
Clos and Mold 2004). A meta-analysis conducted by Jing 
et  al. (2015) indicated that elevated CRP could predict 
poor 5-year OS rates (RR = 2.15, 95 % CI 1.78–2.59) and 
5-year disease-specific survival rates (RR  =  2.12, 95  % 
CI 1.56–2.88). Serum albumin is an important marker 
of nutritional status, and hypoalbuminemia is correlated 
with cachexia (Evans et al. 2008). Mori et al (2015). found 
that the prognostic nutritional index was an independ-
ent prognostic factor for completely resected NSCLC. 
Another study indicated that pretreatment serum albu-
min was an independent prognostic factor for Stage IIIB 
NSCLC that is associated with the response rate to first-
line therapy and survival rates (Tanriverdi et  al. 2015). 
Additionally, hypoalbuminemia is associated with treat-
ment-induced toxicity or complications (Ataseven et al. 
2015; Arrieta et  al. 2010), which also may portend the 
poor prognosis to a certain extent.
Currently, accurate staging of the tumor is of vital 
importance in making a clinical decision of NSCLC. 
The International Association for the study of Lung 
Cancer (IASLC) periodically proposes revisions to the 
TNM staging system, and increasing data indicates 
information used to indicate tumor stage is inadequate 
(McMillan 2008). Performance status (PS) is an effec-
tive complement for tumor stage, partly reflecting 
patient’s tolerance to treatment. For patients with poor 
PS, chemotherapy or radiotherapy are typically not 
applicable. Several large-scale studies indicate that PS 
is an independent prognostic factor for OS in NSCLC 
(Kawaguchi et  al. 2010; Sculier et  al. 2008; Chansky 
et  al. 2009). However, PS is recognized to be subjec-
tive, and its reliability in predicting outcome is compro-
mised (Ando et  al. 2001). By contrast, as an objective 
predictor, GPS is easier to measure, routinely available 
and well standardized. Increasing evidence indicates 
that GPS has independent prognostic value in cancer 
patients (McMillan 2008, 2013). A study of Forrest et al. 
(2004) also indicated that the prognostic value of the 
GPS is independent of tumor stage in NSCLC with an 
HR of 1.88 (95 % CI 1.25–2.84). Our data indicate that 
elevated GPS scores correlate with inferior survival, 
suggesting that the use of anti-inflammatory agents and 
the reinforcement of nutrition possibly may benefit the 
overall survival.
Nevertheless, there are several limitations in the study. 
The comparison between GPS 0 and GPS 1 was not per-
formed as the relevant data were not reported in most 
of the included studies. Different treatment settings in 
studies also inevitably increased the heterogeneity. In 
addition, the large I2 value (54 and 72  %) reflected this 
dilemma and would reduce the reliability of interpret-
ing the results. Some studies incorporating patients with 
small cell lung cancer were not included in our analysis 
(Grose et  al. 2015; Gioulbasanis et  al. 2012). Given that 
Fig. 3 The pooled HRs of OS for GPS 1 versus GPS 2
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the number of patients included in each study for each 
meta-analysis was relative small and half of the included 
articles were retrospective studies that could generate 
bias by variation, a large scale prospective study that uses 
GPS as a stratification factor is required to reduce the 
bias in future.
In conclusion, as an easily obtained and reliable inflam-
matory index, GPS is a promising prognostic indicator in 
patients with NSCLC. More well-designed prospective 
studies are needed to promote the use of GPS in the rou-
tine clinical practice as a complementary prognostic fac-
tor for the current TNM staging system.
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